Clinical Trial Update: A Registry for Patients Taking Uptravi

View source ↗

Summary

A registry study documenting patients taking Uptravi (selexipag) for pulmonary arterial hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Uptravi (selexipag)

Snippet

Sponsor: Actelion | Conditions: Pulmonary Arterial Hypertension | Status: COMPLETED